Androgen receptor contributes to repairing DNA damage induced by inflammation and oxidative stress in prostate cancer

被引:2
|
作者
Debelec Butuner, Bilge [1 ]
Ertunc Hasbal, Nursah [2 ,3 ]
Isel, Elif [1 ]
Roggenbuck, Dirk [4 ,5 ]
Korkmaz, Kemal Sami [2 ]
机构
[1] Ege Univ, Fac Pharm, Dept Pharmaceut Biotechnol, Izmir, Turkiye
[2] Ege Univ, Fac Engn, Dept Bioengn, Canc Biol Lab, Izmir, Turkiye
[3] Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada
[4] Brandenburg Univ Technol Cottbus Senftenberg, Fac Hlth Sci Brandenburg, Senftenberg, Germany
[5] Brandenburg Univ Technol Cottbus Senftenberg, Fac Environm & Nat Sci, Senftenberg, Germany
关键词
Prostate cancer; gamma H2AX; inflammation-induced carcinogenesis; reactive oxygen species; androgen receptor; NKX3.1; NKX3.1; EXPRESSION; HOMEOBOX GENE; HISTONE H2AX; PHOSPHORYLATION; APOPTOSIS; NECROSIS; ATM;
D O I
10.55730/1300-0152.2667
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Androgen deprivation therapy remains the first-line therapy option for prostate cancer, mostly resulting in the transition of the disease to a castration-resistant state. The lack of androgen signaling during therapy affects various cellular processes, which sometimes paradoxically contributes to cancer progression. As androgen receptor (AR) signaling is known to contribute to oxidative stress regulation, loss of AR may also affect DNA damage level and the response mechanism in oxidant and inflammatory conditions of the prostate tumor microenvironment. Therefore, this study aimed to investigate the role of AR and AR-regulated tumor suppressor NKX3.1 upon oxidative stress-induced DNA damage response (DDR) in the inflammatory tumor microenvironment of the prostate. Materials and methods: Intracellular reactive oxygen species (ROS) level was induced by either inflammatory conditioned media obtained from lipopolysaccharide-induced macrophages or oxidants and measured by dichlorodihydrofluorescein diacetate. In addition to this, DNA damage was subsequently quantified by counting gH2AX foci using an immunofluorescence-based Aklides platform. Altered expression of proteins function in DDR detected by western blotting. Results: Cellular levels of ROS and ROS-induced DNA double-strand break damage were analyzed in the absence and presence of AR signaling upon treatment of prostate cancer cells by either oxidants or inflammatory microenvironment exposure. The results showed that AR suppresses intracellular ROS and contributes to DNA damage recognition under oxidant conditions. Besides, increased DNA damage due to loss of NKX3.1 under inflammatory conditions was alleviated by its overexpression. Moreover, the activation of the DDR mediators caused by AR and NKX3.1 activation in androgen-responsive and castration-resistant prostate cancer cells indicated that the androgen receptor function is essential both in controlling oxidative stress and in activating the ROS-induced DDR. Conclusion: Taken together, it is concluded that the regulatory function of androgen receptor signaling has a vital function in the balance between antioxidant response and DDR activation.
引用
收藏
页码:325 / 335
页数:12
相关论文
共 50 条
  • [1] Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of cluterin and its modulation by androgen
    Miyake, H
    Hara, I
    Kamidono, S
    Gleave, M
    Eto, H
    JOURNAL OF UROLOGY, 2003, 169 (04): : 86 - 86
  • [2] Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen
    Miyake, H
    Hara, I
    Gleave, ME
    Eto, H
    PROSTATE, 2004, 61 (04): : 318 - 323
  • [3] The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer
    Ta, Huy Q.
    Gioeli, Daniel
    ENDOCRINE-RELATED CANCER, 2014, 21 (05) : R395 - R407
  • [4] The human androgen receptor regulates DNA damage response (DDR) in prostate cancer
    Asim, Mohammad
    Zecchini, Heather
    Tarish, Firas
    Massie, Charlie
    Baridi, Ajoeb
    Warren, Anne
    Zhao, Wanfeng
    McDuffus, Leigh-Anne
    Mascalchi, Patrice
    Shaw, Greg
    Dev, Harveer
    Wadhwa, Karan
    Wijnhoven, Paul
    Forment, Josep
    Lyons, Scott
    Lynch, Andy
    O'Neill, Cormac
    Zecchini, Vincent
    Rennie, Paul
    Baniahmad, Aria
    Tavare, Simon
    Mills, Ian
    Schulz, Niklas
    Galanty, Yaron
    Helleday, Thomas
    Neal, David
    CANCER RESEARCH, 2016, 76
  • [5] DNA damage signaling in response to oxidative stress in prostate cancer cells
    Ide, Hisamitsu
    Isotani, Shuji
    Kamiyama, Yutaka
    Muto, Satoru
    Horie, Shigeo
    CANCER RESEARCH, 2009, 69
  • [6] Mithramycin suppresses DNA damage repair via targeting androgen receptor in prostate cancer
    Wang, Shan
    Gilbreath, Collin
    Kollipara, Rahul K.
    Sonavane, Rajni
    Huo, Xiaofang
    Yenerall, Paul
    Das, Amit
    Ma, Shihong
    Raj, Ganesh, V
    Kittler, Ralf
    CANCER LETTERS, 2020, 488 : 40 - 49
  • [7] Inflammation, oxidative stress and chemoprevention of prostate cancer
    Nur, Ozten Kandas
    Maarten, C. Bosland
    ANTI-CANCER DRUGS, 2015, 26 : E12 - E12
  • [8] TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression
    Feng, Tingting
    Zhao, Ru
    Sun, Feifei
    Lu, Qiqi
    Wang, Xueli
    Hu, Jing
    Wang, Shiguan
    Gao, Lin
    Zhou, Qianqian
    Xiong, Xueting
    Dong, Xuesen
    Wang, Lin
    Han, Bo
    ONCOGENE, 2020, 39 (02) : 356 - 367
  • [9] TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression
    Tingting Feng
    Ru Zhao
    Feifei Sun
    Qiqi Lu
    Xueli Wang
    Jing Hu
    Shiguan Wang
    Lin Gao
    Qianqian Zhou
    Xueting Xiong
    Xuesen Dong
    Lin Wang
    Bo Han
    Oncogene, 2020, 39 : 356 - 367
  • [10] The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer
    Chellini, Lidia
    Pieraccioli, Marco
    Sette, Claudio
    Paronetto, Maria Paola
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)